All In Biotech

Drug Trial Radar · NCT03829410

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS Mutation

Last checked: Nov 19, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

68

Actual

Start

Jun 24, 2019

Primary completion

Jan 29, 2024

Study completion Jan 29, 2024

Sponsor

Lead sponsor
Cardiff OncologyIndustry
Sponsor type
Industry
First posted
Feb 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line treatment in adult participants who have metastatic colorectal cancer with a KRAS mutation. Participants must have histologically confirmed metastatic and unresectable disease, and previously failed treatment or be intolerant to fluoropyrimidine and oxaliplatin with or without bevacizumab.

Conditions

  • Metastatic Colorectal Cancer
  • KRAS Gene Mutation

Interventions

  • OnvansertibDrug

    Onvansertib orally.

  • BevacizumabBiological

    Bevacizumab intravenously.

  • FOLFIRIDrug

    FOLFIRI intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Up to Day 28
  2. Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to a maximum of 81 weeks
  3. All-Treated Analysis Set: Objective Response Rate (ORR)Time frame: Up to a maximum of 131 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center

    Phoenix, Arizona

  • CARTI Cancer Center

    Little Rock, Arkansas

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University of Kansas Medical Center Research Institute

    Kansas City, Kansas

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Inova Schar Cancer Institute

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.